results and to the marked reduction in toxic mortality associated with this procedure. Over the past decade, there have also been significant Clinical trials involving breast cancer in the Duke University Bone Marrow Transplant Program were evaluimprovements in supportive care for patients undergoing high-dose chemotherapy, including better transfusion supated to assess the association between type of hematopoietic support and treatment-related morbidity/ port and treatment of infections. However, the most substantive improvements have been in hematopoietic support. mortality. Case histories of patients treated with highdose chemotherapy and hematopoietic rescue on three
mediate-dose methotrexate. They were treated to maximal kapheresed three times over 3 h or two times over 4.5 h. Each leukapheresis was performed via a central venous response or to a maximum dose of doxorubicin.
10 Patients with responsive disease were then treated with high-dose catheter using a Cobe Spectra (Lakewood, CO, USA). Cells were stored in the liquid phase of nitrogen. One-third of chemotherapy. In the randomized study, patients in complete remission were randomized to immediate treatment the PBPC was administered via a central venous catheter on either days Ϫ1, 0 and +1 or days +1, +2 and +3. vs treatment at recurrence. Patients with a partial response proceeded immediately to high-dose therapy. During the period under study, 263 patients were treated on the ranDiagnosis of veno-occlusive disease (VOD) of the liver domized trial. The third trial, Duke and CALGB 8782, was a pilot trial of the use of high-dose chemotherapy as con-
The diagnosis of VOD was a clinical diagnosis and required the following findings to be present within 21 days of bone solidation after standard-dose CAF adjuvant therapy for high-risk primary stage II and III breast cancer as defined marrow reinfusion: total bilirubin у2.0 mg/dl, no other identifiable cause of liver dysfunction plus either: (1) hepaby the presence of 10 or more positive axillary lymph nodes. The median age of the patients was 37 and the range tomegaly or right upper quadrant (RUQ) pain; or (2) weight gain (Ͼ5% above baseline body weight) or ascites. of ages was 24- All patients treated with high-dose chemotherapy dred and twenty-eight patients received bone marrow alone, 108 patients with stage IV disease and 20 with stage II/III received autologous bone marrow support (ABMS). Marrow was collected from the posterior iliac crests as predisease. The remainder of the group, 264 patients (199 stage IV and 65 stage II/III), also received CSF primed viously described and stored in the liquid phase of nitrogen. 1 BM was thawed at 37°C in a water bath and infused PBPC ( Table 1) . The 100 day transplant-related mortality for the entire via a central venous catheter on day +1 (96 h following the last dose of chemotherapy).
1 Ninety-one percent of patients group of patients was 42/392 (10.7%). The overall transplant-related mortality was 58/392 (14.8%). Mortality receiving BM alone were also prescribed a colony-stimulating factor post-transplant (firstly either GM-CSF or Gdecreased after the addition of PBPC to BM for hematopoietic support. The 100 day transplant-related mortality for CSF). Administration of the CSF generally continued until neutrophil recovery.
the group of patients treated with BM alone was 26/128 (20.3%), with an overall transplant-related mortality of Technological changes defining the potential of PBPC to augment post-transplant hematologic recovery led us to 31/128 (24.2%). The group that received BM + PBPC experienced a 100 day transplant-related mortality of utilize this approach in patients starting in 1989. Thus, 199 patients received CSF-primed PBPC. CSF priming was 16/264 (6.1%) and an overall transplant-related mortality of 27/264 (10.2%; Table 2 ). begun after the leukocyte count had recovered to Ͼ3000/mm 3 following the last cycle of standard-dose The causes of death secondary to the transplant were varied ( Figure 1 ). In the BM alone group, this included chemotherapy. Patients received granulocyte CSF (G-CSF) or granulocyte-macrophage CSF (GM-CSF), either subcut-VOD (n = 16), pulmonary toxicity five, infection four, hemorrhagic myocarditis two, hemorrhage two, hemolytic aneously or intravenously at various doses for a period ranging from 5 to 8 days. 5 Significant differences between uremic syndrome two. In the BM + PBPC group, the causes of death included infection nine, hemolytic uremic synthe type, dose and schedule of growth factors used were not seen and the patients were analyzed together for the drome eight, pulmonary toxicity four, hemorrhage one, hemorrhagic myocarditis one, veno-occlusive disease one, purpose of this report. The CSF-primed patients were leu- vs 9%).
The characteristics of the patients at presentation with VOD are listed in Table 4 . The mean total bilirubin at presentation was 4.3 mg/dl in the BM alone group, and was 3.7 mg/dl in the BM + PBPC group. The mean day at pressecondary acute myelogenous leukemia one, and CNS toxentation was DOT 15 and 10, respectively. In the BM icity with demyelination two. Autopsy data were available group, 17 (60.7%) had right upper quadrant (RUQ) pain from several patients who experienced VOD and died.
and/or hepatomegaly and the same number had weight gain These studies revealed pathologic findings consistent with and/or ascites. In the BM + PBPC group, two (25%) had VOD (concentric subendothelial thickening of terminal RUQ and/or hepatomegaly, and seven (87.5%) had weight hepatic venules, luminal narrowing by fibrous collagen, gain and/or ascites. etc).
The hematopoietic support evolved over the period of The incidence of VOD was markedly different between review. BM alone was used in 128 patients. PBPC were the two groups. The overall incidence was 36/392 (9.2%) added to BM in 264 patients. This resulted in improvement with a mortality rate among those affected of 17/36 of engraftment of white blood cells (WBC) and platelets. (47.2%). In the BM alone group, the incidence was 28/128
The median day to an absolute neutrophil count у500 (21.9%) with a mortality rate of 16/28 (57.1%). This repcells/mm 3 was 17 days vs 10 days and time to platelet transresents an overall mortality rate of 12.5% for the BM alone group associated with VOD. In the BM + PBPC group, fusion independence (platelet count у20 000 without
Cardiac (1) CNS (2) AML (1) Hemorrhage (1) HUS (8) Infection (4) Pulmonary (4) VOD (16) Cardiac (2) Hemorrhage (2) HUS (2) Infection (4) Pulmonary (5) Figure 1 Causes of death in patients treated with and without PBPC. Transplant-related mortality occurred in 24% (31/128) of patients treated with BM alone, compared to 10% (27/267) of patients receiving BM + PBPC. VOD accounted for 52% and 4% of the deaths in each group respectively (P = 0.001). Absolute number of patients are in parentheses whereas the percentages are plotted. PBPC group constitutes a cohort that was treated more recently, it was suspected that this improvement in mortality was due to supportive care, such as improved treatment of infection or blood bank support. However, the diftransfusion) was 22 days vs 13 days for the BM alone and ference in mortality is almost entirely due to the reduction the BM + PBPC groups, respectively. in mortality associated with VOD. If deaths associated with VOD are excluded, treatment-related mortality in the BM alone group was 11.7% and 9.8% in the BM + PBPC group Discussion (P = NS). This reduction would have been more pronounced except for an increased incidence of hemolyticThe use of high-dose chemotherapy with autologous hemauremic syndrome (HUS) in the BM + PBPC group. The topoietic support for breast cancer has received considerreason for the latter finding is unclear. Perhaps use of CSFable attention over the past decade. This procedure has primed PBPC reduces the severity of endothelial injury, and become more popular as its toxicity has been reduced and therefore the patients in the BM + PBPC group who would clinical results appear encouraging. 4 Innovations in hematohave developed VOD are now surviving longer and the poietic support have greatly reduced the toxicity of this endothelial damage is manifested as HUS. Alternatively, treatment. The use of growth factors has been shown to the reduced period of neutropenia resulting in fewer infecreduce the period of neutropenia after standard-dose tions and days on antibiotics may elicit some protective chemotherapy 13 and after myeloablative therapy. 14 This effects. An infection or prolonged antibiotic administration, period of neutropenia was further abrogated by the addition particularly amphotericin B, may contribute to the of CSF-primed PBPC which also resulted in a marked pathophysiology of VOD. reduction in the mortality rate associated with the proPrevious reports on the incidence of VOD vary widely, cedure. 5, 6 The original pilot trial of high-dose cyclophosranging from 10 to 60% of patients undergoing high-dose phamide, cisplatin and carmustine involved 44 patients with chemotherapy. [15] [16] [17] The syndrome is caused by damage to stage IV breast cancer and revealed a transplant-related the hepatocytes and sinusoids in zone 3 of the liver acinus. mortality of 34%. However, preliminary analysis of patients This damage can be seen on liver biopsy. Microscopic treated for identical indications following the introduction changes include subendothelial swelling with narrowing of of CSF-primed PBPC into the treatment regimen resulted the central vein, engorgement of sinusoids, necrosis of in a vast improvement in transplant-related mortality. Thus, hepatocytes and perivenular fibrosis. 18, 19 Previous studies we set out to conduct a formal retrospective review of the have noted an increased incidence of VOD according to the relationship between hematopoietic support and toxicity.
conditioning regimen. 4 In this study, all patients received The case records of 392 patients treated during this time identical induction chemotherapy and BMT conditioning period were reviewed in order to understand the scope and regimens. Other studies have shown an increased incidence cause of changes in morbidity/mortality. Analysis of the of VOD with the use of cyclosporine and methotrexate. 20, 21 cause of death showed a marked reduction in the incidence However, all patients in this study were rescued with autoof VOD over the period of review. The definition of VOD logous BM and did not receive immunosuppressive agents. was based on the previously published criteria of McDon-
The reason for the association of the use of PBPC with ald et al. 15 This marked reduction was noted to be associaa decreased incidence of VOD, and subsequently, mortality, ted with the addition of PBPC to the method of hematopoietic support. Large amounts of leukocytes are generated during this ther-9: 9.
apy and thus provide a potential increase in the body's cir- plant-related mortality. This is not due to a reduction in
